A Phase 2 interventional study of 50 mg P005672-HCl and Placebo in Acne Vulgaris, sponsored by Almirall, S.A.. Completed at 38 sites in United States. Open to participants aged 12 Years to 45 Years. Per ClinicalTrials.gov, last updated 2019-02-01.
Sponsored by Almirall, S.A. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 373 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.
Among the 373 studies in Acne Vulgaris with a site in United States, this one is the 106th largest by enrollment of the 353 interventional ones that give a count, is one of 14 that started in 2012, is one of 65 in phase 2, and was the 117th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →20 of the 373 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:
Sagimet Biosciences Inc. · Sites in United States
Ages 12+
Integrative Skin Science and Research · Sites in United States
Ages 9+ · Healthy volunteers
Bausch Health Americas, Inc. · Sites in United States
Ages 9–11
Sanofi Pasteur, a Sanofi Company · Sites in United States
Ages 18–45
Sagimet Biosciences Inc. · Sites in United States, Australia
Ages 18–55 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 12 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
373 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 82 · Phase 3 82 · Phase 4 72
First in 2002; this study’s year is marked. 14 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 285 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 78 across the 353 interventional studies, 59 across the 19 observational. Of the 322 that completed or were terminated, 189 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
286 of 373 have an industry lead sponsor. The 10 most frequent:
Almirall, S.A. is the lead sponsor of 66 studies on the registry; 9 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.
Almirall, S.A. has 8 studies filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
9 of the studies in Acne Vulgaris with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07863193Phase 3Sagimet Biosciences Inc.Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA) | 2027-08 |
| NCT06315166PollogenStudy on Using Radiofrequency to Treat Moderate to Severe Acne | 2026-12 |
| NCT02713607University of California, DavisLipidome and Microbiome Profile of Acne | 2027-01 |
| NCT06989840Sagimet Biosciences Inc.Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne | 2027-01 |
| NCT07896486Weill Medical College of Cornell UniversityEvaluating a Brightening Serum for Post-Inflammatory Hyperpigmentation | 2027-01-15 |
Add all 9 to your calendar (.ics) → With an account.
Among the 373 studies in Acne Vulgaris with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and effectiveness of 3 strengths of P005672-HCl compared to placebo for the treatment of moderate to severe facial acne vulgaris.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of acne vulgaris with:
20 to 50 inflammatory lesions (papules, pustules, and nodules) 30 to 100 noninflammatory lesions (open and closed comedones)
Exclusion Criteria:
Within 1 week prior to randomization:
Within 4 weeks prior to randomization:
Within 12 weeks prior to randomization:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One P005672-HCl 50 mg capsule and one Placebo capsule, oral administration, once daily for 12 weeks
Drug: 50 mg P005672-HCl · Drug: Placebo
Two P005672-HCl 50mg capsules, oral administration, once daily for 12 weeks
Drug: 50 mg P005672-HCl
Two P005672-HCl 100mg capsules, oral administration, once daily for 12 weeks
Drug: 100 mg P005672-HCl
Two Placebo capsules matching P005672-HCl, oral administration, once daily for 12 weeks
Drug: Placebo
P005672-HCl administered as an oral capsule(s) once daily
Also known as: WC3035, Sarecycline
Dose-matched Placebo capsule administered as an oral capsule(s) once daily
Also known as: Inactive
P005672-HCl administered as an oral capsule(s) once daily
Also known as: WC3035, Sarecycline
The Absolute Change From Baseline in the Inflammatory Lesion Count at the Final Visit
Time frame: Baseline (Week 0) to Final Visit (Up to Week 12)
The Dichotomized IGA (Investigator Global Assessment) Score at Final Visit
The Investigator Global Assessment Scale (IGA) for Acne Vulgaris Score is a 5-point ordinal scale ranging from 0 to 4. The dichotomized IGA score, where success was defined as at least a 2-grade decrease in the IGA score during the Final Visit as compared to the Baseline Visit.
Time frame: Final Visit (Up to Week 12)
The Absolute Change From Baseline in the Inflammatory Lesion Count at Weeks 1, 2, 4, 8, 12 and the Final Visit
Time frame: Baseline (Week 0) up to Week 12
The Absolute Change From Baseline in the Noninflammatory Lesion Count at Weeks 1, 2, 4, 8, 12, and the Final Visit
Time frame: Baseline (Week 0) up to Week 12
The Percent Change From Baseline in the Inflammatory Lesion Count at Weeks 1, 2, 4, 8, 12, and the Final Visit
Time frame: Baseline (Week 0) up to Week 12
The Percent Change From Baseline in the Noninflammatory Lesion Count at Weeks 1, 2, 4, 8, 12, and the Final Visit
Time frame: Baseline (Week 0) up to Week 12
The Dichotomized IGA Score at Weeks 1, 2, 4, 8, and 12
The Investigator Global Assessment Scale (IGA) for Acne Vulgaris Score is a 5-point ordinal scale ranging from 0 to 4. The dichotomized IGA score, where success was defined as at least a 2-grade decrease in the IGA score during the Final Visit as compared to the Baseline Visit.
Time frame: Baseline to Final Visit (Up to Week 12)
| Milestone | Placebo | P005672-HCl Approximately 0.75 mg/kg/Day | P005672-HCl Approximately 1.5 mg/kg/Day | P005672-HCl Approximately 3.0 mg/kg/Day |
|---|---|---|---|---|
| Started | 73 | 76 | 70 | 66 |
| Completed | 64 | 64 | 60 | 57 |
| Not completed | 9 | 12 | 10 | 9 |
| Withdrew: Adverse event | 1 | 1 | 0 | 4 |
| Withdrew: Lost to follow-up | 3 | 4 | 3 | 3 |
| Withdrew: Withdrawal by subject | 3 | 4 | 4 | 1 |
| Withdrew: Protocol violation | 2 | 1 | 1 | 0 |
| Withdrew: Withdrawn for noncompliance | 0 | 2 | 1 | 0 |
| Withdrew: Abnormal laboratory test results | 0 | 0 | 1 | 0 |
| Withdrew: Positive pregnancy test | 0 | 0 | 0 | 1 |
| Number of Inflammatory Lesions | Placebo | P005672-HCl Approximately 0.75 mg/kg/Day | P005672-HCl Approximately 1.5 mg/kg/Day | P005672-HCl Approximately 3.0 mg/kg/Day |
|---|---|---|---|---|
| The Absolute Change From Baseline in the Inflammatory Lesion Count at the Final Visit | 12.8 ± 14.18 | 14.4 ± 13.01 | 17.6 ± 16.65 | 17.1 ± 11.69 |
The Investigator Global Assessment Scale (IGA) for Acne Vulgaris Score is a 5-point ordinal scale ranging from 0 to 4. The dichotomized IGA score, where success was defined as at least a 2-grade decrease in the IGA score during the Final Visit as compared to the Baseline Visit.
| Participants | Placebo | P005672-HCl Approximately 0.75 mg/kg/Day | P005672-HCl Approximately 1.5 mg/kg/Day | P005672-HCl Approximately 3.0 mg/kg/Day |
|---|---|---|---|---|
| Success | 8 | 11 | 17 | 10 |
| Failure | 64 | 65 | 53 | 56 |
| Count of Inflammatory Lesions | Placebo | P005672-HCl Approximately 0.75 mg/kg/Day | P005672-HCl Approximately 1.5 mg/kg/Day | P005672-HCl Approximately 3.0 mg/kg/Day |
|---|---|---|---|---|
| Change from Baseline at Week 1 | 5.8 ± 9.07 | 5.4 ± 9.28 | 5.4 ± 8.44 | 5.9 ± 8.33 |
| Change from Baseline at Week 2 | 8.4 ± 10.13 | 8.5 ± 10.02 | 8.2 ± 14.45 | 9.7 ± 11.30 |
| Change from Baseline at Week 4 | 10.9 ± 10.04 | 9.3 ± 13.84 | 11.7 ± 15.36 | 12.8 ± 9.96 |
| Change from Baseline at Week 8 | 12.6 ± 12.57 | 13.1 ± 11.89 | 15.0 ± 16.66 | 14.3 ± 12.90 |
| Change from Baseline at Week 12 | 12.8 ± 14.18 | 14.3 ± 13.00 | 17.6 ± 16.65 | 17.1 ± 11.69 |
| Change from Baseline at Final Visit(Up to Week 12) | 12.8 ± 14.18 | 14.4 ± 13.01 | 17.6 ± 16.65 | 17.1 ± 11.69 |
| Count of Noninflammatory Lesions | Placebo | P005672-HCl Approximately 0.75 mg/kg/Day | P005672-HCl Approximately 1.5 mg/kg/Day | P005672-HCl Approximately 3.0 mg/kg/Day |
|---|---|---|---|---|
| Change from Baseline at Week 1 | 5.4 ± 12.99 | 3.8 ± 14.28 | 4.3 ± 14.10 | 5.1 ± 13.83 |
| Change from Baseline at Week 2 | 10.6 ± 16.02 | 9.4 ± 13.58 | 7.8 ± 16.92 | 7.9 ± 14.24 |
| Change from Baseline at Week 4 | 13.0 ± 24.17 | 10.0 ± 17.25 | 9.9 ± 20.58 | 12.7 ± 15.24 |
| Change from Baseline at Week 8 | 16.9 ± 22.52 | 14.3 ± 21.44 | 14.0 ± 22.22 | 15.2 ± 19.04 |
| Change from Baseline at Week 12 | 17.8 ± 21.63 | 17.9 ± 19.85 | 19.1 ± 22.33 | 17.0 ± 21.56 |
| Change from Baseline at Final Visit(Up to Week 12) | 17.8 ± 21.63 | 17.9 ± 19.83 | 19.1 ± 22.33 | 17.0 ± 21.56 |
| Percent Change - Inflammatory Lesions | Placebo | P005672-HCl Approximately 0.75 mg/kg/Day | P005672-HCl Approximately 1.5 mg/kg/Day | P005672-HCl Approximately 3.0 mg/kg/Day |
|---|---|---|---|---|
| Change from Baseline at Week 1 | 19.3 ± 27.82 | 17.2 ± 28.43 | 17.8 ± 26.39 | 19.4 ± 26.17 |
| Change from Baseline at Week 2 | 25.6 ± 29.02 | 26.4 ± 32.60 | 25.8 ± 36.16 | 30.6 ± 35.88 |
| Change from Baseline at Week 4 | 34.1 ± 28.84 | 29.3 ± 38.90 | 34.1 ± 35.27 | 40.0 ± 31.83 |
| Change from Baseline at Week 8 | 37.9 ± 35.60 | 39.8 ± 34.47 | 44.3 ± 37.99 | 44.5 ± 37.62 |
| Change from Baseline at Week 12 | 39.1 ± 43.00 | 43.3 ± 39.70 | 53.6 ± 37.65 | 53.5 ± 35.18 |
| Change from Baseline at Final Visit(Up to Week 12) | 39.1 ± 43.00 | 43.5 ± 39.72 | 53.6 ± 37.65 | 53.5 ± 35.18 |
| Percent change - noninflammatory lesions | Placebo | P005672-HCl Approximately 0.75 mg/kg/Day | P005672-HCl Approximately 1.5 mg/kg/Day | P005672-HCl Approximately 3.0 mg/kg/Day |
|---|---|---|---|---|
| Change from Baseline at Week 1 | 9.7 ± 24.07 | 7.7 ± 26.87 | 8.3 ± 25.20 | 10.6 ± 25.63 |
| Change from Baseline at Week 2 | 19.0 ± 28.36 | 16.7 ± 24.99 | 14.6 ± 30.57 | 16.0 ± 30.37 |
| Change from Baseline at Week 4 | 25.0 ± 37.78 | 18.3 ± 33.17 | 19.2 ± 35.60 | 25.7 ± 29.27 |
| Change from Baseline at Week 8 | 30.5 ± 40.69 | 26.1 ± 38.84 | 27.5 ± 38.54 | 30.4 ± 38.45 |
| Change from Baseline at Week 12 | 35.3 ± 35.32 | 34.3 ± 36.40 | 37.2 ± 38.44 | 32.8 ± 42.59 |
| Change from Baseline at Final Visit(Up to Week 12) | 35.3 ± 35.32 | 34.1 ± 36.28 | 37.2 ± 38.44 | 32.8 ± 42.59 |
The Investigator Global Assessment Scale (IGA) for Acne Vulgaris Score is a 5-point ordinal scale ranging from 0 to 4. The dichotomized IGA score, where success was defined as at least a 2-grade decrease in the IGA score during the Final Visit as compared to the Baseline Visit.
| Participants | Placebo | P005672-HCl Approximately 0.75 mg/kg/Day | P005672-HCl Approximately 1.5 mg/kg/Day | P005672-HCl Approximately 3.0 mg/kg/Day |
|---|---|---|---|---|
| Week 1 — Success | 0 | 3 | 0 | 1 |
| Week 1 — Failure | 72 | 73 | 70 | 65 |
| Week 2 — Success | 2 | 3 | 2 | 2 |
| Week 2 — Failure | 70 | 73 | 68 | 64 |
| Week 4 — Success | 1 | 2 | 0 | 4 |
| Week 4 — Failure | 71 | 74 | 70 | 62 |
| Week 8 — Success | 6 | 6 | 8 | 11 |
| Week 8 — Failure | 66 | 70 | 62 | 55 |
| Week 12 — Success | 8 | 11 | 17 | 10 |
| Week 12 — Failure | 64 | 65 | 53 | 56 |
| Final Visit (Up to Week 12) — Success | 8 | 11 | 17 | 10 |
| Final Visit (Up to Week 12) — Failure | 64 | 65 | 53 | 56 |
Collected over From Screening (up to week -12) to Week 12 plus 30 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/73 (0%) | 13/73 (17.8%) |
| P005672-HCl Approximately 0.75 mg/kg/Day | — | 0/76 (0%) | 15/76 (19.7%) |
| P005672-HCl Approximately 1.5 mg/kg/Day | — | 0/70 (0%) | 8/70 (11.4%) |
| P005672-HCl Approximately 3.0 mg/kg/Day | — | 0/66 (0%) | 7/66 (10.6%) |
| Event | Placebo | P005672-HCl Approximately 0.75 mg/kg/Day | P005672-HCl Approximately 1.5 mg/kg/Day | P005672-HCl Approximately 3.0 mg/kg/Day |
|---|---|---|---|---|
| HeadacheNervous system disorders | 8/73 | 5/76 | 5/70 | 4/66 |
| NauseaGastrointestinal disorders | 4/73 | 6/76 | 1/70 | 2/66 |
| NasopharyngitisInfections and infestations | 5/73 | 4/76 | 2/70 | 2/66 |
285 participants were randomized to double-blind treatment (Safety population)
| Age, Continuous(Years) | Placebo | P005672-HCl Approximately 0.75 mg/kg/Day | P005672-HCl Approximately 1.5 mg/kg/Day | P005672-HCl Approximately 3.0 mg/kg/Day | Total |
|---|---|---|---|---|---|
| Mean | 20.8 ± 6.99 | 19.7 ± 5.92 | 19.9 ± 7.04 | 20.3 ± 7.11 | 20.2 ± 6.74 |
| Sex/Gender, Customized(Participants) | Placebo | P005672-HCl Approximately 0.75 mg/kg/Day | P005672-HCl Approximately 1.5 mg/kg/Day | P005672-HCl Approximately 3.0 mg/kg/Day | Total |
|---|---|---|---|---|---|
| Male | 25 | 29 | 30 | 29 | 113 |
| Female | 48 | 47 | 40 | 37 | 172 |
| Race/Ethnicity, Customized(Participants) | Placebo | P005672-HCl Approximately 0.75 mg/kg/Day | P005672-HCl Approximately 1.5 mg/kg/Day | P005672-HCl Approximately 3.0 mg/kg/Day | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 19 | 21 | 16 | 19 | 75 |
| Not Hispanic or Latino | 54 | 55 | 54 | 47 | 210 |
| Race/Ethnicity, Customized(Participants) | Placebo | P005672-HCl Approximately 0.75 mg/kg/Day | P005672-HCl Approximately 1.5 mg/kg/Day | P005672-HCl Approximately 3.0 mg/kg/Day | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 | 2 |
| Asian | 4 | 4 | 3 | 1 | 12 |
| Black or African American | 17 | 18 | 21 | 13 | 69 |
| Native Hawaiian or Other Pacific islander | 0 | 0 | 0 | 0 | 0 |
| White | 54 | 55 | 46 | 52 | 207 |
| Height(cm) | Placebo | P005672-HCl Approximately 0.75 mg/kg/Day | P005672-HCl Approximately 1.5 mg/kg/Day | P005672-HCl Approximately 3.0 mg/kg/Day | Total |
|---|---|---|---|---|---|
| Mean | 165.80 ± 10.436 | 167.49 ± 9.047 | 167.23 ± 7.380 | 167.33 ± 9.764 | 166.96 ± 9.206 |
| Weight at Baseline(kg) | Placebo | P005672-HCl Approximately 0.75 mg/kg/Day | P005672-HCl Approximately 1.5 mg/kg/Day | P005672-HCl Approximately 3.0 mg/kg/Day | Total |
|---|---|---|---|---|---|
| Mean | 68.47 ± 10.306 | 66.37 ± 8.749 | 69.69 ± 11.861 | 67.31 ± 9.486 | 67.94 ± 10.173 |
Ran from Jun 2012 to primary completion in Nov 2012, 4 months.
Results were first posted in Jan 2019, 6 years 1 month after primary completion. A results delay was requested in Dec 2013.
Of 29 industry-sponsored phase 2 interventional studies under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 4 months is below that.
Counting every sponsor, half of 37 studies reached it within 9 months; a quarter within 6 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.